Dualitas Therapeutics is leading the way in bispecific antibody treatments for inflammatory and immunological (I&I) disorders
Dualitas Therapeutics has raised $65.0M in total funding. The most recent round was Series A. The last funding was announced in September 2025.
Dualitas Therapeutics's investors include Eli Lilly, SV Health Investors, Versant Ventures, Qiming Venture Partners USA, Alexandria Venture Investments.
Dualitas Therapeutics is headquartered in San Francisco, United States.
Dualitas Therapeutics is leading the way in bispecific antibody treatments for inflammatory and immunological (I&I) disorders
Dualitas Therapeutics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Dualitas Therapeutics — Funding & Investors." VCBacked, September 16, 2025, https://www.vcbacked.co/company/dualitas-therapeutics. Accessed July 19, 2026.
VCBacked. (2025). Dualitas Therapeutics — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/dualitas-therapeutics
{{cite web |title=Dualitas Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/dualitas-therapeutics |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated